Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | GPR52 | Q9Y2T5 | 16/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268422 | 1.00 | MAPT (0.62) | MAPTGPR52HCAR2 | |
| SCHEMBL27311625 | 0.97 | MAPT (0.59) | MAPTGPR52HCAR2 | |
| SCHEMBL27310629 | 0.97 | MAPT (0.59) | MAPTGPR52HCAR2 | |
| SCHEMBL27310628 | 0.97 | MAPT (0.59) | MAPTGPR52HCAR2 | |
| SCHEMBL27311627 | 0.97 | MAPT (0.59) | MAPTGPR52HCAR2 | |
| SCHEMBL9608866 | 0.89 | MAPT (0.51) | MAPTGPR52HCAR2 | |
| SCHEMBL16831439 | 0.87 | GPR52 (0.54) | MAPTGPR52HCAR2 | |
| SCHEMBL16831438 | 0.87 | GPR52 (0.54) | MAPTGPR52HCAR2 | |
| SCHEMBL19321725 | 0.84 | GPR52 (0.55) | MAPTGPR52 | |
| SCHEMBL7340918 | 0.84 | MAPT (0.49) | MAPTGPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235516-A1 | DEVELOPMENT OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS AS ANTI-CANCER REAGENTS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-104520279-B | 1,3-benzothiazole-2 (3H)-one and as medicine and the application of cosmetics | Dr August Wolff GmbH & Co.KG Arzneimittel (DE) | 2016-11-30 | — | — | CN | disclosed |
| EP-2852581-B1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| CN-104520279-A | Novel 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR | 2015-04-15 | — | — | CN | disclosed |
| WO-2012069605-A1 | NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2012-05-31 | — | — | WO | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| WO-2004005270-A1 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
| US-6660770-B2 | Inhibit digestion by terminating or blocking synthesis of digestive enzymes by activating trypsin modulating oostatic factor receptor | NORTH CAROLINA STATE UNIVERSITY | 2003-12-09 | — | — | US | disclosed |
| US-20030149103-A1 | Pesticidal activity of functionalized cyclopropanes | NORTH CAROLINA STATE UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| WO-2003051118-A1 | PESTICIDAL ACTIVITY OF FUNCTIONALIZED CYCLOPROPANES | NORTH CAROLINA STATE UNIVERSITY (US) | 2003-06-26 | — | — | WO | disclosed |
| EP-1241941-B1 | PESTICIDAL ACTIVITY OF FUNCTIONALIZED ALKENES | UNIV NORTH CAROLINA STATE (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6521664-B1 | Pesticidal activity of functionalized alkenes | NORTH CAROLINA STATE UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020193436-A1 | Pesticidal activity of functionalized alkenes | NORTH CAROLINA STATE UNIVERSITY | 2002-12-19 | — | — | US | disclosed |
| WO-2002098220-A2 | PESTICIDAL ACTIVITY OF FUNCTIONALIZED ALKENES | NORTH CAROLINA STATE UNIVERSITY (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-1241941-A2 | PESTICIDAL ACTIVITY OF FUNCTIONALIZED ALKENES | NORTH CAROLINA STATE UNIVERSITY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001041543-A2 | PESTICIDAL ACTIVITY OF FUNCTIONALIZED ALKENES | NORTH CAROLINA STATE UNIVERSITY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193436-A1 | Pesticidal activity of functionalized alkenes | VIP, ANPEP, APEH | MAPT 4750/4885GPR52 780/4885HCAR2 1613/4885 |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | MAPT 228/4885GPR52 4536/4885HCAR2 2661/4885 |
| US-20030149103-A1 | Pesticidal activity of functionalized cyclopropanes | DDT, PPIF, CYP4F3 | MAPT 4139/4885GPR52 2429/4885HCAR2 3087/4885 |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | TRPV1, TRPA1, P2RX3 | MAPT 3950/4885GPR52 460/4885HCAR2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.